Risk vs. Reward: Impact of Kidney Biopsies on the Management of Critically Ill Patients

Background: Kidney biopsy is the gold standard for diagnosing many renal diseases, providing crucial information that guides treatment decisions and potentially improves patient outcomes. However, these benefits must be balanced against the risks, particularly in critically ill patients, who are at higher risk of complications due to unstable hemodynamics and coagulation abnormalities. Here we examine the safety and benefit of kidney biopsies in critically ill patients compared to others. Methods: In participants enrolled in the Yale Kidney biobank, we compared the safety and benefit of kidney biopsies between those in the ICU, inpatient wards, and outpatients. The benefit was changes in management, defined as the initiation of steroids, immunosuppressive agents, pheresis, or drug discontinuation post-biopsy. Secondary outcomes included changes in diagnosis, the need for short-term hemodialysis, and chronic hemodialysis dependence. We also assessed safety outcomes using a composite measure of medium/large hematomas, drops in hemoglobin, the need for additional imaging, and interventional radiology procedures. Results: Of the 748 participants, 30 were in the ICU, 202 were inpatient, and 516 were outpatients (Table). Kidney biopsies in the ICU group had a significant impact on management, with 18/30 (60%) of the biopsy results leading to changes in or avoidance of immunosuppressive therapy relative to what would have been the standard of care based on the pre-biopsy diagnosis. The remaining biopsies either confirmed the pre-biopsy diagnosis or resulted in a change between two non-treatment-requiring processes. Safety events were observed in all groups, with the highest rate in the critically ill. Conclusion: Kidney biopsies in the critically ill can significantly impact management but may carry a higher risk of safety events. This risk needs to be compared to the potential benefit and should not be a barrier to a biopsy in select patients.

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.2024dd7bnz12
Primary Topic
Healthcare cost, quality, practices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Risk vs. Reward: Impact of Kidney Biopsies on the Management of Critically Ill Patients

Adrian Llama, Randy L. Luciano, Dennis G. Moledina, Sagar Sadarangani
Journal of the American Society of Nephrology
Healthcare cost, quality, practices
article

Risk vs. Reward: Impact of Kidney Biopsies on the Management of Critically Ill Patients

Adrian Llama, Randy L. Luciano, Dennis G. Moledina, Sagar Sadarangani
article en

Abstract

Background: Kidney biopsy is the gold standard for diagnosing many renal diseases, providing crucial information that guides treatment decisions and potentially improves patient outcomes. However, these benefits must be balanced against the risks, particularly in critically ill patients, who are at higher risk of complications due to unstable hemodynamics and coagulation abnormalities. Here we examine the safety and benefit of kidney biopsies in critically ill patients compared to others. Methods: In participants enrolled in the Yale Kidney biobank, we compared the safety and benefit of kidney biopsies between those in the ICU, inpatient wards, and outpatients. The benefit was changes in management, defined as the initiation of steroids, immunosuppressive agents, pheresis, or drug discontinuation post-biopsy. Secondary outcomes included changes in diagnosis, the need for short-term hemodialysis, and chronic hemodialysis dependence. We also assessed safety outcomes using a composite measure of medium/large hematomas, drops in hemoglobin, the need for additional imaging, and interventional radiology procedures. Results: Of the 748 participants, 30 were in the ICU, 202 were inpatient, and 516 were outpatients (Table). Kidney biopsies in the ICU group had a significant impact on management, with 18/30 (60%) of the biopsy results leading to changes in or avoidance of immunosuppressive therapy relative to what would have been the standard of care based on the pre-biopsy diagnosis. The remaining biopsies either confirmed the pre-biopsy diagnosis or resulted in a change between two non-treatment-requiring processes. Safety events were observed in all groups, with the highest rate in the critically ill. Conclusion: Kidney biopsies in the critically ill can significantly impact management but may carry a higher risk of safety events. This risk needs to be compared to the potential benefit and should not be a barrier to a biopsy in select patients.

Journal of the American Society of NephrologyVol. 35(10S)
Yale University (US)
Openalex Percentile: Top 66%
Healthcare cost, quality, practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.